Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study

Results from two studies (BRAVE-AA1 and BRAVE-AA2) show statistically significant improvement in scalp hair regrowth across both baricitinib dosing groups, compared to placebo Program data will support a submission to achieve a potential first-in-diseas... Biopharmaceuticals Eli Lilly, Incyte, baricitinib, OLUMIANT, Alopecia Areata
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news